1. FT in prognostic of HBV FibroTest: predictive value in HBV

2. FT in prognostic of HCV 1. Diagnosis and clinical options 2. FibroTest: a 4-years prognostic study In this Presentation

3. FT in prognostic of HBV Diagnosis and clinical options

4. FT in prognostic of HCV 95% 5% (For liver injuries Assessment) Diagnosis and clinical options Positive serology Poynard et al, Comp Hepatol 2004

5. FT in prognostic of HBV 5 years prognostic value FibroTest

6. FT in prognostic of HCV Ngo et al, Hepatology AASLD 2007 - Patients and Methods Aim  To prospectively assess the 4-year prognostic value of FibroTest-ActiTest staging compared to biopsy and to HBV-DNA for predicting cirrhosis decompensation and survival. Patients and method  Prospective hospital-based cohort of chronic hepatitis B patients (n=504) (consecutive Ag HBs positive patients with baseline FibroTest-ActiTest HBV DNA measurements)  Mean age 42 yrs,71% males,  30% asian  AgHBe+ 18%  HBV-related complications (main end-point):  liver-related death  liver transplantation  liver failure (ascites, jaundice, hepatic encephalopathy)  variceal bleeding,  hepatocellular carcinoma

7. FT in prognostic of HCV Ngo et al, Hepatology AASLD 2007 - Results 4-year survival without HBV related complications according for FibroTest severity groups -- Minimal fibrosis -- Moderate fibrosis -- severe fibrosis Survival without complications months Baseline FT value n HBV complications Survival without HBV complications 0.00-0.312632 98.9 (97.5-1.00) 0.32-0.581274 91.7 (82.9-1.00) 0.59-1.0011426 72.2 (62.9-81.6) All50432 97.9 (94.9-1.00)

8. FT in prognostic of HCV 4-year survival without HBV related death according for FibroTest severity groups -- Minimal fibrosis -- Moderate fibrosis -- severe fibrosis Survival without complications months Baseline FT value n HBV related death Survival without HBV complications 0.00-0.31263 0100 0.32-0.58127 0100 0.59-1.00114 15 84.2 (76.8-91.6) All504 15 86.9 (80.2-93.5) Ngo et al, Hepatology AASLD 2007 - Results

9. FT in prognostic of HCV Better AUROCs for FibroTest versus HBV-DNA for 4-years survival without HBV complications or death AUROC: 4 years without complications FT AUROC (95%CI) HBV-DNA AUROC (95%CI) p 0.89 (0.82-0.94)0.57 (0.40-0.70)<0.001 AUROC: 4 years without death FT AUROC (95%CI) HBV-DNA AUROC (95%CI) p 0.95 (0.91-0.97)0.55 (0.38-0.68)<0.001 Ngo et al, Hepatology AASLD 2007 - Results Sensivity Specificity -- FibroTest -- HBV DNA Sensivity Specificity -- FibroTest -- HBV DNA

10. FT in prognostic of HCV Similar AUROCs for FibroTest and Biopsy of 4-year survival without HBV complications and death FT AUROC (95%CI) Liver biopsy AUROC (95%CI) p 0.99 (0.90-0.99)0.97 (0.93-0.99)0.32 Ngo et al, Hepatology AASLD 2007 - Results

11. FT in prognostic of HCV Ngo et al, Hepatology AASLD 2007 Conclusions FibroTest’s prognostic valuePossible combinations of FT 4-year prognostic value  similar to that of liver biopsy  better to that of HBV-DNA  With baseline viral load  To improve prediction for  Death  Complications

12. FT in prognostic of HBV